Literature DB >> 15811883

Contemporary management of acute coronary syndrome.

G A Large1.   

Abstract

This review focuses on the modern management of the non-ST elevation acute coronary syndromes (unstable angina and non-ST elevation myocardial infarction). Patients with these syndromes are at varying degrees of risk of (re)infarction and death. This risk can be reliably predicted by clinical, electrocardiographic, and biochemical markers. Aspirin, clopidogrel, heparin (unfractionated or low molecular weight), and anti-ischaemic drugs should be offered to all patients, irrespective of the predicted level of risk. Patients at high risk should also receive a glycoprotein IIb/IIIa receptor inhibitor and should undergo early coronary arteriography with a view to percutaneous or surgical revascularisation. Lower risk patients should undergo non-invasive testing. When inducible myocardial ischaemia is exhibited coronary arteriography should follow. When non-invasive testing is negative, a conservative management strategy is safe.

Entities:  

Mesh:

Substances:

Year:  2005        PMID: 15811883      PMCID: PMC1743242          DOI: 10.1136/pgmj.2004.022590

Source DB:  PubMed          Journal:  Postgrad Med J        ISSN: 0032-5473            Impact factor:   2.401


  55 in total

1.  Effect of glycoprotein IIb/IIIa receptor blocker abciximab on outcome in patients with acute coronary syndromes without early coronary revascularisation: the GUSTO IV-ACS randomised trial.

Authors:  M L Simoons
Journal:  Lancet       Date:  2001-06-16       Impact factor: 79.321

2.  ST depression in ECG at entry indicates severe coronary lesions and large benefits of an early invasive treatment strategy in unstable coronary artery disease; the FRISC II ECG substudy. The Fast Revascularisation during InStability in Coronary artery disease.

Authors:  E Diderholm; B Andrén; G Frostfeldt; M Genberg; T Jernberg; B Lagerqvist; B Lindahl; L Wallentin
Journal:  Eur Heart J       Date:  2002-01       Impact factor: 29.983

3.  An integrated clinical approach to predicting the benefit of tirofiban in non-ST elevation acute coronary syndromes. Application of the TIMI Risk Score for UA/NSTEMI in PRISM-PLUS.

Authors:  D A Morrow; E M Antman; S M Snapinn; C H McCabe; P Theroux; E Braunwald
Journal:  Eur Heart J       Date:  2002-02       Impact factor: 29.983

4.  ACC/AHA 2002 guideline update for the management of patients with unstable angina and non-ST-segment elevation myocardial infarction--summary article: a report of the American College of Cardiology/American Heart Association task force on practice guidelines (Committee on the Management of Patients With Unstable Angina).

Authors:  Eugene Braunwald; Elliott M Antman; John W Beasley; Robert M Califf; Melvin D Cheitlin; Judith S Hochman; Robert H Jones; Dean Kereiakes; Joel Kupersmith; Thomas N Levin; Carl J Pepine; John W Schaeffer; Earl E Smith; David E Steward; Pierre Theroux; Raymond J Gibbons; Joseph S Alpert; David P Faxon; Valentin Fuster; Gabriel Gregoratos; Loren F Hiratzka; Alice K Jacobs; Sidney C Smith
Journal:  J Am Coll Cardiol       Date:  2002-10-02       Impact factor: 24.094

5.  Platelet glycoprotein IIb/IIIa inhibitors in acute coronary syndromes: a meta-analysis of all major randomised clinical trials.

Authors:  Eric Boersma; Robert A Harrington; David J Moliterno; Harvey White; Pierre Théroux; Frans Van de Werf; Anneke de Torbal; Paul W Armstrong; Lars C Wallentin; Robert G Wilcox; John Simes; Robert M Califf; Eric J Topol; Maarten L Simoons
Journal:  Lancet       Date:  2002-01-19       Impact factor: 79.321

6.  Prognosis in the thrombolysis in myocardial ischemia III registry according to the Braunwald unstable angina pectoris classification.

Authors:  Benjamin M Scirica; Christopher P Cannon; Carolyn H McCabe; Sabina A Murphy; H Vernon Anderson; William J Rogers; Peter H Stone; Eugene Braunwald
Journal:  Am J Cardiol       Date:  2002-10-15       Impact factor: 2.778

7.  The prognostic value of B-type natriuretic peptide in patients with acute coronary syndromes.

Authors:  J A de Lemos; D A Morrow; J H Bentley; T Omland; M S Sabatine; C H McCabe; C Hall; C P Cannon; E Braunwald
Journal:  N Engl J Med       Date:  2001-10-04       Impact factor: 91.245

8.  Interventional versus conservative treatment for patients with unstable angina or non-ST-elevation myocardial infarction: the British Heart Foundation RITA 3 randomised trial. Randomized Intervention Trial of unstable Angina.

Authors:  K A A Fox; P A Poole-Wilson; R A Henderson; T C Clayton; D A Chamberlain; T R D Shaw; D J Wheatley; S J Pocock
Journal:  Lancet       Date:  2002-09-07       Impact factor: 79.321

9.  Use of a monoclonal antibody directed against the platelet glycoprotein IIb/IIIa receptor in high-risk coronary angioplasty.

Authors: 
Journal:  N Engl J Med       Date:  1994-04-07       Impact factor: 91.245

10.  Benefit of clopidogrel in patients with acute coronary syndromes without ST-segment elevation in various risk groups.

Authors:  Andrzej Budaj; Salim Yusuf; Shamir R Mehta; Keith A A Fox; Gianni Tognoni; Feng Zhao; Susan Chrolavicius; David Hunt; Matyas Keltai; Maria Grazia Franzosi
Journal:  Circulation       Date:  2002-09-24       Impact factor: 29.690

View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.